Edgewise plans to start a Phase 3 trial for HCM drug EDG-7500 in Q4, citing 12-week Phase 2 data showing NT-proBNP response rates above 74% across patient subtypes.
June 16, 2026 11:40 AM EDT
Edgewise to advance heart drug into Phase 3 following mid-stage data update
Ayisha Sharma
News Reporter
Edgewise Therapeutics has shared plans to advance its drug candidate for a genetic heart disease into a registrational study on the back of updated Phase …
Edgewise Therapeutics Reports Improvements In Heart Drug Trial - Edgewise Therapeutics (NASDAQ:EWTX)
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage
Heartseed, World's First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed
Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and…
As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the…
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion…
